Walleye Capital’s Seres Therapeutics MCRB Stock Holding History

Walleye Capital’s Portfolio MCRB Stock Details MCRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-245	Closed	-$11.7K	–	5283
2023 Q3	$11.7K	Buy	+245	New	+$18.7K	﹤0.01%	4459
2023 Q1	–	Sell	-1,290	Closed	-$144K	–	4197
2022 Q4	$144K	Buy	+1,290	New	+$173K	﹤0.01%	2228

Other funds holding MCRB

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Walleye Capital's MCRB Position: Q1 2024 in Review

Walleye Capital sold out of Seres Therapeutics (MCRB) in Q1 2024, closing a stake of 1,997 shares — an estimated $55.9K sold.

Walleye Capital first reported a position in MCRB in Q2 2019 and held it in 7 quarters. The position peaked at $2.05M in Q1 2023. 99 funds tracked by Wall St. Rank hold MCRB as of Q1 2024.

Walleye Capital reported no remaining Seres Therapeutics position as of Q1 2024 after selling out during the quarter.
Walleye Capital sold 1,997 Seres Therapeutics shares in Q1 2024, an estimated $55.9K.
Walleye Capital first reported a position in Seres Therapeutics in Q2 2019 and held it in 7 quarters.
Walleye Capital's Seres Therapeutics position peaked at $2.05M in Q1 2023.
99 funds tracked by Wall St. Rank held Seres Therapeutics as of Q1 2024.

Based on Walleye Capital's 13F filing for Q1 2024, filed 15 May 2024.